The virus that causes COVID-19 is completely new to the human population. This raises a lot of questions, and concerns, for pregnant women. The goal of the ASPIRE study is to provide answers to pregnant women and their families.
By enrolling in ASPIRE, you will help find answers and help women worldwide.
Through the ASPIRE study, a large group of women will be studied starting from the earliest stages of pregnancy. Any symptoms will be tracked and tests will be collected for COVID-19 antibodies throughout the pregnancy. Plus, outcomes will be followed for both the mom and the baby.
Interested participants will sign up directly with ASPIRE.
Once you do, they’ll send you a consent form to sign, and you’ll be on your way. The process includes completing a study questionnaire; providing frequent, but quick updates on your phone; providing blood samples (you can do this at home) and allowing for a review of your medical records. You’ll also provide updates on your baby’s health for the first year of life.
Although the ASPIRE study continues throughout the entire pregnancy, most information will be needed during the first trimester.
Solid epidemiologic data about the effects of prior viral epidemics on pregnancy (SARS, H1N1) is limited due to a lack of high-quality prospective studies that follow women from the earliest stages of pregnancy. Historically, the first trimester has been inaccessible to medical research because most women don’t arrive at their initial obstetrician appointment until close to the end of the first trimester – several weeks after the critical period of fetal development has closed.
To circumvent this challenge, a team at UCSF (University of California at San Francisco) has partnered with the Society for Assisted Reproductive Technology (SART), the only nationwide resource in the country which tracks early pregnancies from the moment of conception.
More Information/Joining the Study
Download the flyer.
Watch the video.
Go to https://aspire.ucsf.edu/ for more background on the study and access a link to sign up.